Hypofractionated Radiotherapy in Intermediate-Risk Prostate Cancer Patients: Long-Term Results.

Maurizio ValerianiMario Di StasoGiuseppe FacondoGianluca VulloVitaliana De SanctisGiovanni Luca GravinaMilena di Genesio PagliucaMattia Falchetto OstiPierluigi Bonfili

Published in: Journal of clinical medicine (2022)

HyRT is effective and safe regardless of the use of IGRT. PSA at first follow-up is an easily accessible prognostic factor that may help the clinicians to identify patients who require a treatment intensification.

Keyphrases

prognostic factors
prostate cancer
radiation therapy
early stage
palliative care
radical prostatectomy
radiation induced
small cell lung cancer
benign prostatic hyperplasia
replacement therapy
breast cancer risk